Drug Stocks In News: Teva Pharmaceutical Industries (NYSE:TEVA), Allergan (NYSE:AGN), Dynavax Technologies Corporation (NASDAQ:DVAX), ISIS Pharmaceuticals (NASDAQ:ISIS)

Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announces the launch of the generic equivalent to Lunesta(R) (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was -0.68% in last session and finished the day at $49.61. Traded volume was 2,806.00million shares in the last session and the average volume of the stock remained 7.21million shares. The beta of the stock remained 0.59.

RPS has entered into a U.S. co-promotional partnership with Allergan, Inc. (NYSE:AGN), a global leader in eye care, to increase awareness of dry eye disease related to elevated MMP-9 in tears. Allergan, Inc. (NYSE:AGN) rose 3.09 percent to $127.80 Tuesday on volume of 5.86million shares. The intra-day range of the stock was $123.97 to $127.96. Allergan, Inc. (NYSE:AGN) has a market capitalization of $38.23billion.

Dynavax Technologies Corp. (NASDAQ:DVAX) was the recipient of a significant growth in short interest in the month of January. As of March 31st, there was short interest totalling 30,405,093 shares, a growth of 17.0% from the March 14th total of 25,976,848 shares. Dynavax Technologies Corporation (NASDAQ:DVAX)’s stock on Apr 15, 2014 reported a decrease of -3.33% to the closing price of $1.45. Its fifty two weeks range is $0.98 -$2.68. The total market capitalization recorded $381.14million. The overall volume in the last trading session was 4.84million shares. In its share capital, DVAX has 262.88million outstanding shares.

ISIS Pharmaceuticals Inc (NASDAQ:ISIS) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $35.00 price target on the stock. Zacks’ analyst wrote, “Isis’ net loss of $0.21 per share was wider than the Zacks Consensus Estimate of a loss of $0.17. On Tuesday, shares of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) dropped -0.57% to close the day at $32.99. Company return on investment (ROI) is -7.50% and its monthly performance is recorded as -29.61%. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) quarterly revenue growth is -32.27%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone